While treating advanced renal cell carcinoma, Temsirolimus may cause various side effects. Understanding these adverse reactions and their management, as well as mastering correct storage conditions, helps ensure treatment safety and efficacy.
I. Common Side Effects
1. Systemic reactions:
(1) Side effects occurring in more than 30% of patients include rash, fatigue, oral mucositis, nausea, edema, and decreased appetite.
(2) These symptoms usually appear early in treatment and are mostly mild to moderate in severity.
2. Laboratory abnormalities:
More than 30% of patients experience anemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, lymphocytopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia, thrombocytopenia, and elevated AST.
II. Serious Side Effects Requiring Vigilance
1. Allergic and infusion reactions:
During the first infusion, facial flushing, chest pain, dyspnea, hypotension, or even anaphylactic shock may occur, which can be life-threatening.
2. Hyperglycemia and hyperlipidemia:
About 89% of patients have elevated blood glucose, 87% elevated cholesterol, and 83% elevated triglycerides, potentially requiring initiation of glucose-lowering or lipid-lowering therapy.
3. Infection and immunosuppression:
May increase the risk of opportunistic infections, including Pneumocystis jirovecii pneumonia (PJP), especially when used with corticosteroids; prophylaxis should be considered.
4. Interstitial lung disease:
(1) Manifests as dyspnea, cough, hypoxemia, fever; some cases can be fatal.
(2) Regular chest imaging is recommended even in asymptomatic patients.
5. Renal impairment:
Rapidly progressive and even fatal acute renal failure may occur; some cases are unresponsive to dialysis.
6. Other serious reactions:
Bowel perforation, abnormal wound healing, cerebral hemorrhage, proteinuria, and even nephrotic syndrome have been reported.
III. Methods to Alleviate Side Effects
1. For allergic reactions:
(1) Routine administration of antihistamines (e.g., diphenhydramine 25-50 mg) 30 minutes before infusion.
(2) If an allergic reaction occurs during infusion, stop immediately, observe for 30-60 minutes, and restart at a slower infusion rate under medical guidance if appropriate.
2. Control blood glucose and lipids:
(1) Regularly monitor blood glucose, cholesterol, and triglycerides before and during treatment.
(2) Based on test results, initiate or adjust insulin, oral hypoglycemics, or lipid-lowering drugs as prescribed.
3. Prevent infection:
(1) Practice good personal hygiene and avoid crowded places.
(2) If corticosteroids are used concomitantly, discuss the need for PJP prophylaxis with your doctor.
4. Manage oral mucositis:
(1) Use a soft-bristled toothbrush, avoid irritating foods, and maintain oral hygiene.
(2) Use alcohol-free mouthwash if necessary.
5. Skin care:
(1) Rash is common; use gentle moisturizers and cleansers, and avoid scratching.
(2) Seek medical attention for severe rash.
6. Monitor renal function:
(1) Regularly check serum creatinine and urine protein.
(2) If nephrotic syndrome (massive proteinuria, edema, etc.) occurs, discontinue Temsirolimus.
7. Report symptoms promptly:
Inform your doctor immediately if you experience new or worsening respiratory symptoms, abdominal pain, blood in stool, extreme thirst, or increased urine output.
IV. Storage Environment Requirements
1. Temperature control:
(1) Temsirolimus injection and its accompanying diluent must be stored refrigerated at 2°C to 8°C.
(2) Do not freeze.
2. Protection from light:
Protect from light during storage in original packaging and during preparation; avoid indoor bright light and direct sunlight.
3. Stability after preparation:
(1) The solution mixed with the diluent is stable for 24 hours below 25°C.
(2) After further dilution with normal saline, infusion should be completed within 6 hours.
4. Prevent leakage:
Temsirolimus is a cytotoxic drug; special handling procedures should be followed during preparation and disposal to avoid spillage or direct skin contact.
